Experimental Diabetes Drug Raises Certain Cancer Risks

06/27/11 Bristol-Myers Squibb and AstraZeneca are developing a new diabetes medication, but the experimental drug, although found to be effective in the two-year study, left participants with increased bladder and breast cancers, said Reuters. Of the dapagliflozin studies completed, 1.4 percent of patients treated with the drug developed some form of cancer, versus 1.3 percent of the [...]

+

-

 

Press Release

06/26/11 Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a long-term (104 weeks) Phase 3 clinical study which showed that the investigational compound dapagliflozin added to metformin sustained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) from 52-weeks to 104-weeks, in adults with type 2 diabetes when compared to glipizide ...

+

-

 

Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients ...

06/26/11 SAN DIEGO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results from a long-term (104 weeks) Phase 3 clinical study which showed that the investigational compound dapagliflozin added to metformin sustained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) from 52-weeks to 104-weeks, in adults with type 2 diabetes ...

+

-